Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellgenic Autologous Mesenchymal Stromal Cells
- Development stage
- Unknown
- Lead developer
- Cellgenic
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular, Subcutaneous
01
Overview
Cellgenic Autologous Mesenchymal Stromal Cells refer to a cell therapy product provided by Cellgenic, a division of the Global Stem Cells Group. The therapy involves isolating mesenchymal stem cells (MSCs) from a patient's own tissue—typically adipose tissue or bone marrow—processing them, and re-administering them to the same patient. These cells are utilized for their regenerative, immunomodulatory, and anti-inflammatory properties. MSCs are known to home to sites of injury and release paracrine factors that stimulate tissue repair and modulate immune responses. The product is marketed as part of a suite of regenerative medicine offerings for various clinical applications, including orthopedic conditions, aesthetic treatments, and chronic inflammatory diseases, though it is typically provided as a clinical service rather than a traditionally regulated pharmaceutical drug candidate in a formal R&D pipeline.
- Brand names
- Cellgenic
- Other names
- Autologous MSCsMesenchymal stem cellsAutologous mesenchymal stem cell therapy
Beyond the preview
Go deeper on Cellgenic Autologous Mesenchymal Stromal Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellgenic Autologous Mesenchymal Stromal Cells.